Abstract
Zolpidem is among the most frequently prescribed hypnotic drugs for those who suffer from insomnia. Recent media reports drew attention to driving impairment after zolpidem misuse. This review summarizes the available data on the effects of recommended use and misuse of zolpidem on driving ability and traffic safety. Both experimental studies and roadside evidence were taken into account. From these studies it must be concluded that patients should fully comply with the prescription instructions of zolpidem, i.e. to take the medication just prior to a full 8 hours of uninterrupted sleep. If this strategy is adopted, zolpidem is a safe alternative to benzodiazpine hypnotics and zopiclone who do show significant driving impairment the morning following bedtime administration. However, to ensure traffic safety higher dosages than recommended (10 mg) or allowing less than 8 hours between zolpidem intake and actual operation of a motor vehicle should be avoided.
Keywords: Zolpidem, driving, accidents, compliance
Current Drug Safety
Title: Zolpidem and Traffic Safety - The Importance of Treatment Compliance
Volume: 2 Issue: 3
Author(s): Joris C. Verster, Edmund R. Volkerts, Berend Olivier, William Johnson and Laura Liddicoat
Affiliation:
Keywords: Zolpidem, driving, accidents, compliance
Abstract: Zolpidem is among the most frequently prescribed hypnotic drugs for those who suffer from insomnia. Recent media reports drew attention to driving impairment after zolpidem misuse. This review summarizes the available data on the effects of recommended use and misuse of zolpidem on driving ability and traffic safety. Both experimental studies and roadside evidence were taken into account. From these studies it must be concluded that patients should fully comply with the prescription instructions of zolpidem, i.e. to take the medication just prior to a full 8 hours of uninterrupted sleep. If this strategy is adopted, zolpidem is a safe alternative to benzodiazpine hypnotics and zopiclone who do show significant driving impairment the morning following bedtime administration. However, to ensure traffic safety higher dosages than recommended (10 mg) or allowing less than 8 hours between zolpidem intake and actual operation of a motor vehicle should be avoided.
Export Options
About this article
Cite this article as:
Verster C. Joris, Volkerts R. Edmund, Olivier Berend, Johnson William and Liddicoat Laura, Zolpidem and Traffic Safety - The Importance of Treatment Compliance, Current Drug Safety 2007; 2 (3) . https://dx.doi.org/10.2174/157488607781668882
DOI https://dx.doi.org/10.2174/157488607781668882 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Approaches on Novel Topical Delivery Systems for Atopic Dermatitis Treatment
Recent Patents on Drug Delivery & Formulation Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews 3D-QSAR of Novel Phosphodiesterase-4 Inhibitors by Genetic Function Approximation
Medicinal Chemistry Neutrophil Activation Induced by Plant Lectins: Modulation of Inflammatory Processes
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Flow-Independent Exhaled Nitric Oxide Parameters in the Assessment of Airway Diseases
Current Topics in Medicinal Chemistry Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design Homogeneous Time Resolved Fluorescence Assay to Measure Histamine Release
Combinatorial Chemistry & High Throughput Screening The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) The Role of Bacterial DNA in Inflammatory and Allergic Disease
Recent Patents on Inflammation & Allergy Drug Discovery Neutrophil Proteome: Lessons from Different Standpoints
Protein & Peptide Letters Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD
Current Drug Targets Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Flexible Bronchoscopy Biopsy Tools and Techniques to Optimize Diagnostic Yield: A Contemporary Review
Current Respiratory Medicine Reviews Community-Acquired Pneumonia in Children
Recent Patents on Inflammation & Allergy Drug Discovery Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry Editorial [Hot Topic: Recent Advances and Future Prospect in Protease Targeting (Executive Editor: B. Turk) ]
Current Pharmaceutical Design Immunoproteomics for Serological Diagnosis of Hypersensitivity Pneumonitis Caused by Environmental Microorganisms
Current Protein & Peptide Science VIP and Drug Design
Current Pharmaceutical Design Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Growing up in the Web of Social Networking: Adolescent Development and Social Media
Adolescent Psychiatry